Positive News SentimentPositive NewsNASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $24.44 +0.21 (+0.87%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$23.96▼$24.9050-Day Range$16.49▼$25.2852-Week Range$7.60▼$25.58Volume231,051 shsAverage Volume446,529 shsMarket Capitalization$864.69 millionP/E RatioN/ADividend YieldN/APrice Target$29.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Harrow alerts: Email Address Harrow MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside21.1% Upside$29.60 Price TargetShort InterestBearish15.74% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to $0.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.28 out of 5 starsMedical Sector784th out of 936 stocksPharmaceutical Preparations Industry363rd out of 436 stocks 2.5 Analyst's Opinion Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 3 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.74% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow has recently decreased by 3.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 3.3 News and Social Media Coverage News SentimentHarrow has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Harrow this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat Follows4 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have not sold or bought any company stock.Percentage Held by Insiders13.67% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.51) to $0.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -26.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -26.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 12.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Harrow Stock (NASDAQ:HROW)Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesJuly 3, 2024 | benzinga.comTop 3 Health Care Stocks That May Crash This QuarterJune 24, 2024 | seekingalpha.comHarrow Successfully Manufactures Triesence; Management Credibility SoarsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 20, 2024 | businesswire.comHarrow Provides TRIESENCE® Relaunch UpdateJune 7, 2024 | investorplace.comThe Top 7 Growth Stocks to Buy and Hold Until 2030June 5, 2024 | businesswire.comHarrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension StudyMay 15, 2024 | insidermonkey.comHarrow Health, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call TranscriptMay 15, 2024 | businesswire.comHarrow to Present at Two Investor Conferences in MayJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | finance.yahoo.comHarrow Inc (HROW) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic AdvancesMay 15, 2024 | finance.yahoo.comHarrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo FinanceMay 15, 2024 | markets.businessinsider.comHarrow Health’s Promising Growth Trajectory and Strong Financial Outlook Reinforce Buy RatingMay 14, 2024 | seekingalpha.comHarrow, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 13, 2024 | investorplace.comHROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)May 13, 2024 | businesswire.comHarrow Announces First Quarter 2024 Financial ResultsMay 13, 2024 | businesswire.comHarrow Names Greg DiPasquale as Senior Vice President, Head of CommercialMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)See More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$29.60 High Stock Price Target$34.40 Low Stock Price Target$25.00 Potential Upside/Downside+21.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,410,000.00 Net Margins-22.59% Pretax Margin-21.88% Return on Equity-39.82% Return on Assets-8.13% Debt Debt-to-Equity Ratio3.06 Current Ratio3.00 Quick Ratio2.75 Sales & Book Value Annual Sales$130.19 million Price / Sales6.64 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book12.16Miscellaneous Outstanding Shares35,380,000Free Float30,545,000Market Cap$864.69 million OptionableOptionable Beta0.77 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsAVEO PharmaceuticalsNASDAQ:AVEOKindred BiosciencesNASDAQ:KINLifeVantageNASDAQ:LFVNBiohavenNYSE:BHVNXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 12,580 shares on 7/26/2024Ownership: 0.249%Allspring Global Investments Holdings LLCBought 2,048 shares on 7/26/2024Ownership: 0.006%Private Capital Management LLCBought 217,896 shares on 7/18/2024Ownership: 8.514%Westside Investment Management Inc.Sold 1,635 shares on 7/17/2024Ownership: 0.593%Opaleye Management Inc.Bought 100,600 shares on 5/29/2024Ownership: 11.081%View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $11.20 on January 1st, 2024. Since then, HROW shares have increased by 118.2% and is now trading at $24.44. View the best growth stocks for 2024 here. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.03. The business earned $34.59 million during the quarter, compared to analyst estimates of $34.37 million. Harrow had a negative trailing twelve-month return on equity of 39.82% and a negative net margin of 22.59%. Who are Harrow's major shareholders? Top institutional investors of Harrow include Westside Investment Management Inc. (0.59%), Bank of New York Mellon Corp (0.25%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary, Richard L Md Lindstrom and Horn R Lawrence Van. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and CymaBay Therapeutics (CBAY). This page (NASDAQ:HROW) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
